Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload – the RELATH study

References

• Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, et al.. Relationship between transfusion regimen and suppression of erythropoiesis in betathalassaemia major. Br J Haematol 1995;89:473–8.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997;37:135–40.
   PubMed Web of Science ®Google Scholar
• Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239–52.
   PubMed Web of Science ®Google Scholar
• Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al.. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319–24.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986–95.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al.. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227–31.
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al.. Survival and causes of death in thalassaemia major. Lancet 1989;2:27–30.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al.. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411–6.
   PubMed Web of Science ®Google Scholar
• Batra AS, Acherman RJ, Wong WY, Wood JC, Chan LS, Ramicone E, et al.. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol 2002;70:306–12.
   PubMed Web of Science ®Google Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006;4:91–6.
   PubMedGoogle Scholar
• Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003:40–61.
   Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al.. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–73.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051–2.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al.. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574–8.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al.. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417–23.
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al.. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597–602.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al.. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455–62.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al.. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501–8.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Damanhouri G, et al.. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458–65.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–99.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al.. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al.. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327–31.
   PubMed Web of Science ®Google Scholar
• Iron overload disorders among Hispanics–San Diego, CA, USA, 1995. MMWR Morb Mortal Wkly Rep 1996;45:991–3.
   Google Scholar
• Araújo A, Drelichman G, Cançdo RD, Watman N, Magalhães SM, Duhalde M, et al.. Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations. Hematology 2009;14:22–32.
   PubMed Web of Science ®Google Scholar
• Penchaszadeh VB. Community genetics in Latin America: challenges and perspectives. Community Genet 2000;3:124–7.
   Google Scholar
• Penchaszadeh VB, Beiguelman B. Medical genetic services in Latin America: report of a meeting of experts. Rev Panam Salud Publica [document on the internet]. 1998, vol. 3, no. 6 [cited 2009 Oct 22]. p. 409–420. Available from: http://www.scielosp.org/scielo.php?script = sci_arttext&pid = S1020-49891998000600013&lng = en&nrm = iso
   Google Scholar
• Roldan A, Gutierrez M, Cygler A, Bonduel M, Sciuccati G, Torres AF. Molecular characterization of β-thalassemia genes in an Argentine population. Am J Hematol 1997;54:179–82.
   PubMed Web of Science ®Google Scholar
• Loureiro MM, Rozenfeld S, Carvalho MS, Portugal RD. Factors associated with hospital readmission in sickle cell disease. BMC Blood Disord 2009;9:2.
   PubMedGoogle Scholar
• Cuéllar-Ambrosi F, Mondragón MC, Gigueroa M, Préhu C, Galactéros F, Ruiz-Linares A. Sickle cell anemia and β-globin gene cluster haplotypes in Colombia. Hemoglobin 2000;24:221–5.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al.. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5–11.
   PubMed Web of Science ®Google Scholar
• Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–78.
   PubMed Web of Science ®Google Scholar
• Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38:30–6.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, et al.. Comparison of organ dysfunction in transfused patients with SCD or β Thalssemia. Am J Hematol 2005;80:70–4.
   PubMed Web of Science ®Google Scholar
• Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al.. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574–82.
   PubMed Web of Science ®Google Scholar
• Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, et al.. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 2008;48:1971–80.
   PubMed Web of Science ®Google Scholar
• Fernandes JL, Fabron A, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009;94:1776–7.
   PubMed Web of Science ®Google Scholar
• Low LC. Growth, puberty and endocrine function in beta-thalassemia major. J Pediatr Endocrinol Metabl 1997;10:175–84.
   PubMed Web of Science ®Google Scholar
• Gulati R, Bhatia V, Argarwal SS. Early onset of endocrine abnormalities in beta-thalssemia major in a developing country. J Pediatr Endocrinol Metab 2000;13:651–6.
   PubMed Web of Science ®Google Scholar
• Soliman AT, el-Zalabany M, Amer M, Ansari BM. Growth and pubertal development in transfusion-dependent children and adolescents with thalassemia major and sickle cell disease: a comparative study. J Trop Pediatr 1999;4591:23–30.
   Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al.. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187–93.
   PubMed Web of Science ®Google Scholar
• Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high risk beta-thalassemia. Blood 2000;95:1229–36.
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26–36.
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, et al.. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusions are non-linear, and are associated with iron load and liver injury. Blood 2009;114:4632–8.
   PubMed Web of Science ®Google Scholar